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A Phase II Randomized Trial of Gefitinib Alone or with
Tegafur/Uracil Treatment in Patients with Pulmonary
Adenocarcinoma Who had Failed Previous Chemotherapy
Yuh-Min Chen, MD, PhD,*†‡ Wen-Chien Fan, MD,§ Chun-Ming Tsai, MD,*† Shih-Hao Liu, MD,
Jen-Fu Shih,* Teh-Ying Chou, MD, PhD,¶ Chieh-Hung Wu, MD,* Kun-Ta Chou, MD,*
Yu-Chin Lee, MD,* Reury-Perng Perng, MD, PhD,* and Jacqueline Whang-Peng, MD‡
Background: Tegafur/uracil (UFT) is suitable for metronomic che-
motherapy because of its underlying antiangiogenesis mechanism.
This study aimed to assess the efficacy of adding daily oral UFT to
gefitinib treatment in patients with pulmonary adenocarcinoma who
had failed previous chemotherapy.
Methods: Taiwanese patients who had adenocarcinoma of the lung
and failed previous chemotherapy were randomized into gefitinib
250 mg daily alone (G) or plus daily oral UFT (GU). From
November 2005 to August 2009, 115 patients were enrolled.
Results: There were 58 patients in the G arm and 57 in the GU arm.
One-year progression-free survival (PFS) was 18% in the G arm and
36.7% in the GU arm (p  0.03). Fifty-four patients had tissue
samples available for tumor epidermal growth factor receptor
(EGFR) sequence analysis: 16 classical mutations and 8 wild types
in the G arm, and 20 classical mutations and 10 wild-types in the GU
arm. The addition of UFT significantly improved PFS in patients
with EGFR mutations (14.4 versus 7.6 months, p  0.0061).
Forty-three patients underwent tumor tissue microvessel density
measurement, and a trend favoring the addition of UFT to gefitinib
treatment was found in those with low microvessel density (median
PFS: 11.8 versus 2.8 months, p 0.0536). The median survival time
was 18.3 months in the G arm and 23.6 months in the GU arm
(p  0.381).
Conclusion: Gefitinib plus UFT treatment had better PFS than
gefitinib alone treatment. Gefitinib is effective in patients with
EGFR mutations, and the addition of UFT treatment produced better
PFS in these patients with mutations.
Key Words: Epidermal growth factor receptor (EGFR), Gefitinib,
Non-small cell lung cancer, Salvage therapy, UFT (tegafur/uracil).
(J Thorac Oncol. 2011;6: 1110–1116)
Epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs) are active agents against advanced non-
small cell lung cancer (NSCLC) when given as second-line or
third-line single-agent therapy for advanced NSCLC, com-
pared with the best supportive care or standard salvage
chemotherapy.1–3 EGFR-TKI treatment is more effective in
women, patients who never smoked, and patients with ade-
nocarcinoma. In these populations, such treatment is associ-
ated with favorable objective response rates, progression-free
survival (PFS), and possibly overall survival.2,4,5
Investigators have tried many ways to enhance EGFR-
TKI efficacy against NSCLC, such as adding chemotherapeu-
tic agent(s) or an antiangiogenesis agent. Four large phase III
randomized trials with concurrent administration of gefitinib
or erlotinib with standard platinum-doublet chemotherapy
showed no improved survival compared with chemotherapy
alone.6–9 A possible reason for the lack of efficacy in these
trials was the potential antagonism between the constituents
of the combination therapy: EGFR-TKIs induce G1-phase
cell cycle arrest in EGFR wild-type tumor cells, which
protects cells from the cytotoxic effects of cell cycle phase-
dependent chemotherapeutic agents.10
Tegafur/uracil (UFT, one capsule of UFT contains
tegafur 100 mg and uracil 224 mg) is an orally active
preparation of 5-fluorouracil (5-FU). Meta-analysis of adju-
vant chemotherapy with single-agent UFT therapy after sur-
gery showed a significant survival benefit, with a hazard ratio
of 0.799.11 In addition, UFT was found to be effective against
chemo-naive, advanced NSCLC when combined with cispla-
tin treatment.12–14 Experimental studies have shown that UFT
and its metabolites, -hydroxybutyric acid and 5-FU, inhibit
tumor angiogenesis, both in vitro and in vivo, and inhibit the
growth and migration of endothelial cells in culture. This
inhibitory effect on tumor-associated angiogenesis was more
marked when the drugs were administered continuously at
low doses.15–17 Thus, UFT may be suitable for metronomic
chemotherapy because of its underlying antiangiogenesis
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mechanism.18 Combining EGFR-TKIs, such as gefitinib,
which inhibit tumor cell growth and block synthesis of
angiogenic proteins by tumor cells, with UFT, which has the
potential to inhibit tumor-associated angiogenesis—two dif-
ferent mechanisms of action—probably could achieve better
treatment efficacy than single-agent treatment alone.19
Our previous studies showed the high efficacy of ge-
fitinib treatment in Taiwanese patients with adenocarcinoma
who failed previous chemotherapy.20,21 In this study, we
investigated whether the addition of daily UFT treatment to
gefitinib treatment could enhance the treatment effect of
gefitinib in terms of 1-year PFS.
PATIENTS AND METHODS
The study protocol was approved by the institutional
review board of our hospital (VGHIRB 94-09-03; Clinical-
Trials.gov protocol registration system NCT01037998). Pa-
tients with adenocarcinoma of the lung who had failed pre-
vious chemotherapy were entered into the study after giving
informed consent. Eligibility criteria included a histological
or cytological diagnosis of adenocarcinoma of the lung, stage
IIIB with malignant pleural effusion or stage IV (6th edition
tumor, node, metastasis classification), age 18 years, and
failed previous chemotherapy; a performance status of 0 to 3
on the World Health Organization scale; clinically measur-
able disease; no previous radiotherapy directed at the mea-
surable lesion(s); and adequate bone marrow reserve with a
white blood cell count 4000/mm3. Patients previously
treated with a 5-FU-related chemotherapeutic agent, such as
5-FU or UFT; with interstitial lung disease; with inadequate
liver function (total bilirubin 1.5 times and alanine amino-
transferase/aspartate transaminase 3 times the upper limit
normal); or inadequate renal function with creatinine 2.0
mg/dl were excluded from the study.
Eligible patients were randomized and stratified by sex
and smoking history into either gefitinib treatment (G arm) or
gefitinib plus UFT treatment (GU arm). No smoking history
was defined as patients who had never smoked or smoked less
than 100 cigarettes in their lifetime. All patients in the G arm
received gefitinib at a daily oral dose of 250 mg. All patients
in the GU arm received UFT, one capsule orally, twice daily,
in addition to a dose of daily gefitinib 250 mg. Treatment was
given until disease progression, patient refusal, or develop-
ment of intolerable toxicity.
With respect to dose modifications, gefitinib and
UFT were stopped for 1 or 2 weeks if the patient suffered
from grade 3 or worse toxicity; gefitinib and UFT could be
restarted from a 50% dose once the toxicity was reduced to
grade 2 or less, except in cases of drug-induced pneumo-
nitis, in which the treatment would be permanently
stopped. A subsequent dose escalation to the original level
was allowed provided that the patient tolerated the doses
given at the 50% level.
Subsequent complete blood cell count and serum bio-
chemistry studies were performed 2 weeks and 4 weeks after
the beginning of treatment and then every 6 weeks. Drug-
related adverse events and toxicities were recorded using the
Common Toxicity Criteria of the National Cancer Institute
(version 3.0). The Lung Cancer Symptom Scale was recorded
before treatment, every 4 weeks thereafter, and when the
patient completed or went off the study. Evaluation of re-
sponse was performed every 8 weeks after the beginning of
treatment. Types of response were assessed with the use of
the RECIST.22
This study was designed to enroll at least 53 qualified
patients in each arm. This calculation was based on the Simon
design, which assumes that the true 1-year PFS rate for the best
treatment is 10% better than that for the others.23 We assumed
that the smaller 1-year PFS rate was 15% and the higher one was
25%, with a power of 0.9 and a p value of 0.05, and that each
treatment group required 53 qualified patients. PFS was calcu-
lated from the date of administration of the first dose to the
earliest sign of disease progression, as determined by means of
the RECIST,22 or death from any cause. If disease progression
had not occurred at the time of the last follow-up visit, PFS was
considered to have been censored at the time of the last fol-
low-up visit. Survival was measured from administration of the
first dose until the date of death or last follow-up. For statistical
analysis, the Kaplan-Meier method with a log-rank test was used
for survival analysis. The Cox-regression analysis test, including
UFT treatment or not, EGFR mutation or wild type, with a
smoking habit or not, response to first-line treatment or not, and
with or without skin rash after treatment, was performed for
multivariate PFS analysis. For the statistical analysis of the Lung
Cancer Symptom Scale, the Mann-Whitney U test was used for
a comparison of the two arms of treatment, and the Wilcoxon
signed ranks test was used for a comparison before and after
treatment. The SPSS statistical program (SPSS Inc., Chicago,
IL) was used.
EGFR mutation analysis was performed with nucleo-
tide sequence analysis. The VarientSEQr Resequencing
Primer Set (Applied Biosystems, Inc., Foster, CA) was se-
lected for mutational analysis of the tyrosine kinase domain,
exons 18 to 21 of the EGFR gene. Genomic DNA was
extracted from paraffin blocks, exons 18 to 21 were ampli-
fied, and uncloned polymerase chain reaction fragments were
sequenced and analyzed in both sense and antisense direc-
tions for the presence of heterozygous mutations. Normal
control DNA provided by the ABI company (Applied Bio-
systems, Inc.) was used for wild-type control. All the se-
quence variations were confirmed by multiple, independent
polymerase chain reaction amplifications and repeated se-
quencing reactions. Classical EGFR mutations were defined
as those with exon 19 deletions or exon 21 L858R.
Microvessel density (MVD) measurement was as-
sessed by means of immunohistochemistry. The slices
were deparaffinized and dehydrated in graded alcohol.
Heat-induced antigen retrieval was performed. The anti-
CD34 monoclonal antibody was the first antibody. The first
antibody kit and immunohistochemical kit were purchased
from a commercial company. The procedures were per-
formed according to the instructions, and positive and nega-
tive control groups were regularly used. The degree of an-
giogenesis was determined by means of MVD measurement
in the defined areas of tissue sections, based on the Weidner
method.24 Each slide was first scanned at low magnification
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(100) to determine five “hotspot” areas where the number
of microvessels was at a maximum. MVD was counted in
each of the five hotspot areas on a slide at high magnification
(200). Any one brown-stained endothelial cell or cell clus-
ter that was obviously different from the peripheral and con-
nective tissues was counted as a single vessel, and a branch
Patients randomly assigned
(n=115)
Arm G
(n=58)
Arm GU
(n=57)
All received G 
treatment
All received 
GU treatment
Eligible for 
analysis 
(n=58)
Eligible for 
analysis 
(n=57)
PFS and toxicity
Response by RECIST
Completed LCSS (n=49)
EGFR sequence (n=24)
MVD measurement (n=22) 
Completed LCSS (n=54)
EGFR sequence (n=30)
MVD measurement (n=21) 
FIGURE 1. CONsolidated Standards of Reporting Trials dia-
gram for the study. G, gefitinib; GU, gefitinib  UFT; PFS,
progression-free survival; LCSS, Lung Cancer Symptom
Scale; EGFR, epidermal growth factor receptor; MVD, mi-
crovessel density; UFT, Tegafur/uracil.
FIGURE 2. PFS of 115 patients treated with gefitinib (G)
alone (n  58) or plus UFT (GU) (n  57). One-year PFS
was 18% in the G arm and 36.7% in the GU arm (p 
0.03). The median PFS was 5.3 months (95% CI: 3.2–7.5
months) in the G arm and 8.3 months (95% CI: 3.2–13.4
months) in the GU arm (p  0.0355). The hazard ratio for
the addition of UFT to gefitinib treatment was 0.65 (95% CI:
0.43–0.97), with a p value of 0.0373. PFS, progression-free
survival; UFT, Tegafur/uracil; CI, confidence interval.
FIGURE 3. Survival curve of 115 patients with adenocarci-
noma treated with gefitinib (G) alone (n  58) or plus UFT
(GU) (n  57). The median survival time was 18.3 months
(95% CI: 15.3–21.4 months) in the G arm and 23.6 months
(95% CI: 8.8–38.4 months) in the GU arm (p  0.381). The
1-year survival rate was 64.8% in the G arm and 68.1% in
the GU arm. The 2-year survival rate was 27.7% in the G
arm and 47.1% in the GU arm. UFT, Tegafur/uracil.
TABLE 1. Patient Characteristics (n  115)
Variables
Patient Number (%)
Gefitinib Gefitinib  UFT
Patient number 58 57
Sex
Male 33 (57) 37 (65)
Female 25 (43) 20 (35)
Age: mean (range) 64 (37–87) 65 (30–85)
WHO performance status
0 6 (10) 2 (4)
1 28 (48) 44 (77)
2 23 (40) 9 (16)
3 1 (2) 2 (4)
Present treatment as
Second line 31 (53) 25 (44)
Third line 25 (43) 31 (54)
Fourth line 2 (4) 1 (2)
Smoking
Yes 28 (48) 25 (44)
No 30 (52) 32 (56)
Type of response to first-line
chemotherapy
PR 13 (22) 10 (17)
SD 34 (59) 38 (67)
PD 11 (19) 9 (16)
EGFR mutation status
Mutated 16 (67) 20 (67)
Wild type 8 (33) 10 (33)
UFT, Tegafur/uracil; WHO, World Health Organization; PR, partial response; SD,
stable disease; PD, progressive disease; EGFR, epidermal growth factor receptor.
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construct with discrete breaks was also counted as a single
vessel. The average counting was recorded as the value of the
MVD. The median value of MVD in the study population was
used as the cutoff value for patients with a high or low MVD
measurement when performing statistical analysis (low
MVD  median value and high MVD  median value).
RESULTS
From November 2005 to August 2009, 115 patients
were enrolled, including 58 patients who received G treat-
ment and 57 who received GU treatment. The clinical char-
acteristics of these patients are listed in Table 1. There was
no statistical difference in the clinical characteristics of the
two arms of treatment. All patients were assessable for
toxicity profile and treatment response. Figure 1 shows the
CONsolidated Standards of Reporting Trials diagram. Fifty-four
patients had tumor tissue samples available for EGFR mutation
analysis (24 in the G arm and 30 in the GU arm), and 43 had
samples available for anti-CD34 MVD measurements (22 in the
G arm and 21 in the GU arm).
FIGURE 4. UFT prolonged PFS in patients with a
classical EGFR mutation. A, 20 EGFR-mutated pa-
tients received GU (median: 14.4 months, 95%
CI: 13–15.8 months, censor 8) and 16 received G
(median: 7.6 months, 95% CI: 6.7–8.6 months,
censor 3) (p  0.0061). B, 10 EGFR wild-type pa-
tients received GU (median 4.9 months, 95% CI:
1–8.9 months, censor 1) and 8 received G (me-
dian: 2 months, 95% CI: 0.7–3.2 months, censor 2)
(p  0.8979). C, 27 EGFR status unknown patients
received GU (median: 5 months, 95% CI: 0.2–9.7
months, censor 4) and 34 received G (median 5
months, 95% CI: 4–6 months, censor 1) (p 
0.4246). UFT significantly prolonged the PFS of
EGFR-mutated patients only. UFT, Tegafur/uracil;
PFS, progression-free survival; EGFR, epidermal
growth factor receptor; CI, confidence interval.
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After 8 weeks of treatment, 20 patients achieved a
partial response (PR) in the G arm (overall response rate of
35%), and 21 achieved a PR in the GU arm (overall response
rate of 37%) (p  0.847). Stable disease was found in 18
(31%) and 22 (39%) patients, respectively. Progressive dis-
ease was found in 20 (34%) and 14 (24%) patients, respec-
tively. Among 54 patients with tissue samples available for
EGFR mutation analysis, 36 had classical EGFR mutations
(12 exon 19 deletions and 4 exon 21 L858R mutations in the
G arm, and 17 exon 19 deletions and 3 exon 21 L858R
mutations in the GU arm). When considering EGFR mutation
status, 3 of 36 classical EGFR-mutated patients had disease
progression after 8 weeks of treatment (8%), whereas 10 of
18 (56%) patients with wild-type EGFR and 21 of 61 (34%)
patients with an unknown EGFR mutation status had disease
progression (p  0.003). Seven of 22 patients with high
MVD had a PR to gefitinib-containing treatment, whereas 5
of 21 patients with low MVD had a PR (32% versus 24%,
p  0.228).
After a median follow-up of 14 months, the median
PFS was 5.3 months in the G arm (n  58, censor 6) and 8.3
months in the GU arm (n  57, censor 13) (p  0.0355). The
hazard ratio for the addition of UFT to gefitinib treatment was
0.65 (95% confidence interval [CI]: 0.43–0.97), with a p
value of 0.0373. One-year PFS was 18% in the G arm and
36.7% in the GU arm (p 0.03, Fig. 2). The median survival
time was 18.3 months in the G arm (censor 27) and 23.6
months in the GU arm (censor 29) (p  0.381, Fig. 3). The
1-year and 2-year survival rates were 64.8% and 27.7% in the
G arm and 68.1% and 47.1% in the GU arm, respectively.
Median PFS was 10.8 months (n  36, censor 11) in
patients with an EGFR mutation and 2.4 months in those with
wild-type EGFR (n  18, censor 3) (p  0.0009). Median
PFS was 5 months in 61 patients (censor 5) whose EGFR
mutation status was unknown. The addition of UFT signifi-
cantly improved PFS in those patients with an EGFR muta-
tion (20 with GU treatment, median 14.4 months, censor 8;
16 with G treatment, median 7.6 months, censor 3; p 
0.0061), whereas there was no difference in wild-type pa-
tients or patients with an unknown EGFR mutation (Fig. 4).
The median value of MVD measurement performed in 43
patients was 36 (Fig. 5). Of the patients with low MVD, those
taking GU (n  11, median 11.8 months) had a longer PFS
than those taking G alone (n  10, median 2.8 months) (p 
0.0536). There was no difference in patients with high MVD
who were treated with GU (n  10, median 4.9 months) or G
(n  12, median 6.4 months) (p  0.9106).
When considering all 115 patients together, PFS was
significantly better in those who had a better performance
status (p  0.0001), those without a smoking habit (p 
0.015), those with skin rash (p  0.0179), those whose
disease could be controlled by the present treatment (p 
0.0001), those with a classical EGFR mutation (p  0.0009),
and those who received UFT treatment in addition to gefitinib
treatment (p  0.0355) (Table 2). The Cox regression anal-
ysis identified EGFR mutation (hazard ratio: 0.32, 95% CI:
0.15–0.7, p  0.004), skin rash (hazard ratio: 0.37, 95% CI:
0.17–0.82, p  0.0147), UFT treatment (hazard ratio: 0.53,
95% CI: 0.26–1.08, p  0.0794), smoking habit (hazard
ratio: 1.84, 95% CI: 0.9–3.75, p  0.0941), and response to
first-line chemotherapy (hazard ratio: 2.98, 95% CI: 1.17–
7.63, p  0.0226) as significant prognostic factors for PFS.
All patients enrolled in the study were eligible for
toxicity evaluation. The toxicities were few and mild in
severity in both arms. Toxicities more than grade 2 included
1 with grade 3 skin rash in the G arm and 1 with grade 3
paronychia in the GU arm.
Overall, 103 patients (54 in the G arm and 49 in the GU
arm) completed the Lung Cancer Symptom Scale question-
naire. The results of the completed questionnaire showed that
there was no statistically significant difference in the scales
between the G and GU arms, either before or 8 weeks after
treatment, or when the patient went off study. When consid-
ering all the treated patients together, there was a slight
decrease in the scores of all items between pretreatment and
8 weeks after treatment or after the patient had gone off the
treatment, except hemoptysis, disease severity, and quality of
life, which showed no difference after 8 weeks of treatment
or when the patient had gone off the treatment.
FIGURE 5. Immunohistochemical
staining with anti-CD34 monoclo-
nal antibody for microvessel den-
sity (MVD) examinations. A, High
MVD: a lot of brown-stained endo-
thelial cells, cell clusters, and
branch constructs with discrete
breaks are noted. B, Low MVD: few
brown-stained endothelial cells, cell
clusters, and branch constructs
with discrete breaks are noted
(magnification 400).
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DISCUSSION
Those populations with clinical characteristics predict-
ing a better response to EGFR-TKI also have a relatively high
incidence of somatic mutations in the region of the EGFR
gene that encodes the tyrosine kinase domain.25,26 Studies
have shown that tumor cells with a base-pair deletion at exon
19 (del746_A750) or a point mutation at exon 21 (L858R)
were highly responsive to EGFR-TKIs.27–29
The efficacy of UFT treatment alone in patients with
advanced NSCLC is modest, with a response rate of only
8.7%.12 It was found that patients with NSCLC tumors
containing low thymidylate synthase may benefit from UFT
treatment.30 Investigators found adjuvant UFT chemotherapy
prolonged survival only among patients with stage IB ade-
nocarcinoma with EGFR wild-type tumors (hazard ratio 
0.34, p  0.013) but not among those with EGFR-mutant
tumors. An in vitro experiment with lung adenocarcinoma
cell lines showed the half maximal inhibitory concentrations
of EGFR mutant cells to FU, one of the metabolites of UFT,
were higher than those of wild-type cells, indicating that
EGFR wild-type cells are more sensitive to FU than mutant
cells. Thus, tumor EGFR status might influence the effect of
adjuvant chemotherapy with UFT,31 if we consider the sur-
vival benefit of adjuvant chemotherapy with UFT to be based
on the cytotoxic effect against tumor cells. Whether prolon-
gation of survival in stage IB EGFR wild-type adenocarci-
noma is truly due to the UFT cytotoxic effect is debatable.
Our study is the first to show that the addition of a
cytotoxic agent improves the effect of EGFR-TKIs in pro-
longing patient PFS. We believe that this was not due just to
the cytotoxic effect of UFT, because the dosage of UFT used
was lower than usual, and single-agent UFT treatment in
patients with advanced NSCLC previously treated with che-
motherapy is less effective. The dose of UFT used in our
study was only half or similar to the dose used in adjuvant
UFT studies in early-stage patients, and UFT increased the
PFS of our patients with an EGFR mutation who received
gefitinib treatment but not that of the wild-type EGFR pa-
tients who received gefitinib treatment. Thus, there may still
be some differences in the underlying mechanism of the
increase in PFS between stage IB patients who received UFT
adjuvant chemotherapy and stage IV patients who received
combination treatment with gefitinib. UFT and its metabolites
inhibit tumor angiogenesis and inhibit the growth and migra-
tion of endothelial cells in culture. This inhibitory effect was
more marked when the drugs were administered continuously
at low doses15–17 and may be one of underlying mechanisms
of the increase in PFS of our gefitinib-treated patients. Fur-
thermore, it is likely that EGFR-TKI, especially gefitinib, is
effective only in EGFR-mutated adenocarcinoma.29 Thus,
UFT has an additive effect with gefitinib in EGFR-mutated
adenocarcinoma only, whereas it is less useful in EGFR
wild-type adenocarcinoma that does not respond to gefitinib
treatment. In addition, there is also a possible pharmacoki-
netic interaction between UFT and gefitinib that is still
unknown at present.
In a small study of adjuvant chemotherapy with UFT in
stage I NSCLC, high tumor MVD with anti-CD105 staining
showed significant improvement in survival compared with
surgery alone.17 In this study, anti-CD34 MVD measurement
showed a trend toward prolonging time to disease progression
by adding UFT in patients with low MVD. Methods of MVD
measurement vary widely, with the result that its clinical
application is more limited.32 Tumor burden is minimal when
UFT is used in an adjuvant setting, whereas it is relatively
large when UFT is used in advanced disease. The antiangio-
genic effect of UFT may have some limitations or a ceiling
effect, with the result that its effects can only be seen in
patients with low MVD when they have advanced disease.
TABLE 2. Progression-Free Survival of 115 Patients Treated
with Gefitinib Alone or with UFT
Patient
Number
Median
PFS (mo)
p
(Log-Rank)
Sex
Male 70 5.3 0.379
Female 45 7.8
Performance status
0 8 5.3 0.0001
1 72 8
2 32 2
3 3 1
Present treatment as
Second line 56 7.3 0.2371
Third line 56 5.4
Fourth line 3 2.5
Smoking
Yes 53 2.4 0.015
No 62 8.1
Response to present
treatment
PR 41 9.7 0.0001
SD 40 10.7
PD 34 1.5
Response to first-line
chemotherapy
PR 23 5.4 0.0604
SD 72 7.8
PD 20 1.9
Skin rash
Yes 47 9.6 0.0179
No 68 2.8
UFT treatment
Yes 57 8.3 0.0355
No 58 5.3
EGFR mutation status
Mutated 36 10.8 0.0009
Wild type 18 2.4
Unknown 61 5
Microvessel density
Low 21 9.7 0.6728
High 22 5.4
PR, partial response; SD, stable disease; PD, progressive disease; UFT, Tegafur/
uracil; EGFR, epidermal growth factor receptor.
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Although there was no statistically significant differ-
ence, the discrepancy in the performance status in the two
study arms (more patients had a better performance status in
the GU arm) and the potential for interpretation bias should
be noted. The sample size of this study was relatively small,
and less than half of the tumors were tested for the presence
of EGFR mutations. Further studies stratified by EGFR mu-
tation status or phase III randomized studies of patients with
adenocarcinoma are suggested to confirm the UFT effect on
gefitinib treatment.
In conclusion, gefitinib is highly effective in Taiwan-
ese patients with adenocarcinoma of the lung who have a
classical EGFR mutation and who have failed previous
chemotherapy. The addition of daily low-dose UFT treat-
ment produced even better PFS in these patients with
classical EGFR mutations.
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